A Case of Mantle Cell Lymphoma Treated with Autologous Stem Cell Transplantation and Rituximab | Zendy

So Yeon Oh | Zendy; Moon Ju Jang | Zendy; Sei Kyung Chang | Zendy; Doyeon Oh | Zendy; So Young Chong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Case of Mantle Cell Lymphoma Treated with Autologous Stem Cell Transplantation and Rituximab

Author(s) -

So Yeon Oh,

Moon Ju Jang,

Sei Kyung Chang,

Doyeon Oh,

So Young Chong

Publication year - 2006

Publication title -

the korean journal of hematology

Language(s) - English

Resource type - Journals

eISSN - 2092-9129

pISSN - 1738-7949

DOI - 10.5045/kjh.2006.41.3.215

Subject(s) - mantle cell lymphoma , medicine , rituximab , autologous stem cell transplantation , regimen , chop , lymphoma , oncology , transplantation , surgery

Mantle cell lymphoma is a subtype of aggressive non-Hodgkin's lymphoma and usually presents in advanced stages. When treated with a regimen such as CHOP, the median survival is about three years. More aggressive front-line therapy with the hyper-CVAD regimen or high-dose therapy with stem cell support has shown encouraging results in several trials. The addition of rituximab to the chemotherapy regimens, or high-dose therapy, increased the response and survival rates in patients with mantle cell lymphoma. We report a case of mantle cell lymphoma that was successfully treated with aggressive front-line treatment strategies. The patient achieved complete remission with initial hyper-CVAD regimen, and was consolidated with autologous stem cell transplantation and subsequent rituximab. (Korean J Hematol 2006;41:215-219.)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research